Recombinant Mouse T-lymphocyte activation antigen CD86 (Cd86), partial

What is the molecular function of CD86 in T-cell activation pathways?

CD86 (B7-2) serves as a critical costimulatory molecule found on antigen-presenting cells (APCs) that interacts with CD28 on T cells to provide the essential "second signal" for T-cell activation. This interaction is fundamental to proper T-lymphocyte proliferation and interleukin-2 (IL-2) production. CD86 engagement with CD28 initiates signaling through the phosphatidylinositol 3-kinase-protein kinase B (Akt) pathway and growth factor-receptor-bound protein 2 (Grb2), resulting in several key cellular events: increased IL-2 production, upregulation of CD25 (the IL-2 receptor α chain), entry of T cells into the cell cycle, and enhanced T-cell survival through upregulation of the antiapoptotic molecule Bcl-XL . Methodologically, researchers investigating this pathway should consider using CD80/CD86−/− mouse models to isolate the specific contributions of these costimulatory molecules to T-cell activation in various experimental contexts.

How can researchers accurately measure CD86 expression in various mouse tissue samples?

For quantitative measurement of mouse CD86 in research samples, ELISA-based methods provide reliable detection across multiple sample types. The single-wash 90-minute SimpleStep ELISA® has been validated for serum, heparin plasma, EDTA plasma, and citrate plasma samples with high reproducibility (coefficient of variation ranging from 4.74% to 8.9%) . When analyzing expression patterns, researchers should be aware of sample-specific recovery rates, which typically range from 96-120% depending on the sample type, with serum showing the highest average recovery at 113% . For cell-specific expression analysis, flow cytometry remains the gold standard, allowing researchers to correlate CD86 expression with specific cell populations and activation states. When designing experiments, include appropriate controls and standardization procedures to account for inter-assay variability.

What are the key differences between CD80 and CD86 in experimental models?

While CD80 and CD86 both bind to CD28 and CTLA-4, they exhibit distinct kinetics, expression patterns, and functional properties in mouse models. CD86 is constitutively expressed at low levels on APCs and rapidly upregulated upon activation, whereas CD80 expression is primarily induced after activation with slower kinetics . Functionally, studies using CD80−/−, CD86−/−, and CD80/CD86−/− mice have revealed both overlapping and distinct roles in T-cell activation. In viral infection models, CD80/CD86−/− mice show severely impaired primary antiviral CD8+ T-cell responses and neutralizing antibody production compared to wild-type controls . These differences become particularly evident during long-term immune surveillance, where CD80/CD86−/− mice exhibit altered CD8+ T-cell phenotypes with impaired IFN-γ production and secondary expansion capabilities . When designing experiments to differentiate between CD80 and CD86 functions, researchers should consider using both single knockout and double knockout models to isolate specific contributions of each molecule.

How does CD86 deficiency specifically affect CD8+ T-cell responses during viral infections?

In CD80/CD86−/− mouse models infected with murine gammaherpesvirus 68 (MHV-68), CD8+ T-cell responses show multiple distinct impairments across different phases of the immune response. During primary expansion, antiviral CD8+ T-cell responses are severely compromised, with significantly reduced numbers of virus-specific CD8+ T cells observed in the spleen at day 14 post-infection compared to wild-type controls . This defect is particularly pronounced during the acute phase of infection.

The memory phase reveals even more nuanced defects: CD80/CD86−/− mice show impaired gamma interferon (IFN-γ) production capacity and secondary expansion upon antigenic challenge . Interestingly, at days 42 and 97 post-infection, the absolute numbers of virus-specific CD8+ T cells become comparable between CD80/CD86−/− and wild-type mice, but functional differences persist . Researchers investigating CD86's role in antiviral immunity should therefore evaluate not just numerical parameters but also functional markers including cytokine production, proliferative capacity, and phenotypic markers of memory formation at multiple timepoints throughout the infection timeline.

What methodological approaches can differentiate between CD28-dependent and CD28-independent effects of CD86?

Distinguishing CD28-dependent from CD28-independent effects of CD86 requires sophisticated experimental approaches. Research with MHV-68 infection models has revealed a CD28-independent role for CD80/CD86 in controlling viral reactivation . This methodological distinction can be accomplished through parallel experiments using CD80/CD86−/− and CD28−/− mice, analyzing differences in outcomes between these models.

Additionally, researchers can employ blocking antibodies against specific interaction partners—such as anti-CTLA-4 monoclonal antibodies—to temporarily disrupt specific pathways while leaving others intact . In the cited study, researchers administered 200 micrograms of anti-CTLA-4 monoclonal antibody (clone UC10-4F10-11) intraperitoneally every 2-3 days to investigate CTLA-4-independent effects . This approach allows for temporal control of pathway inhibition and can reveal compensatory mechanisms. For comprehensive mechanistic understanding, these approaches should be combined with biochemical analyses of downstream signaling pathways and transcriptomic profiling to identify differential gene expression patterns between the different experimental conditions.

How does CD86 expression influence B cell repertoire development and tolerance mechanisms?

CD86 plays a significant role in B cell development, diversification, and tolerance induction. In partial RAG deficiency (pRD) models, where B cell receptor (BCR) repertoire development is compromised, CD86-mediated signaling contributes to dysregulated peripheral B cell activation . This is evidenced by the observation of somatic hypermutation (SHM) and class-switch recombination (CSR) in phenotypically naive B cell compartments of pRD patients, suggesting premature and dysregulated activation .

Methodologically, researchers investigating CD86's role in B cell tolerance should analyze polyreactivity of antibodies produced by single-sorted B cells at different developmental stages . In pRD models, elevated frequencies of polyreactive clones in CD38int B cells compared to healthy controls indicate defects in peripheral B cell tolerance . Additionally, analysis of immunoglobulin gene usage patterns, particularly decreased usage of distal Jκ gene segments (Jκ4 and 5), can provide insight into receptor editing processes that normally contribute to tolerance induction . Flow cytometric analysis of surface immunoglobulin expression, including unusual co-expression of IgM and IgG, can further reveal abnormalities in B cell development and activation that may be influenced by CD86-mediated signaling .

What experimental approaches are recommended for studying CD86-mediated CD8+ T-cell memory formation?

Investigating CD86's role in CD8+ T-cell memory formation requires multifaceted experimental approaches. Based on findings that CD80/CD86−/− mice show altered memory CD8+ T-cell phenotypes with impaired IFN-γ production and secondary expansion capabilities , researchers should implement several methodological strategies:

• Temporal analyses: Track virus-specific CD8+ T cells at multiple timepoints (early activation, expansion, contraction, and memory phases) using MHC tetramers or pentamers specific for viral epitopes.

• Functional assays: Assess memory T-cell functionality through ex vivo restimulation with viral peptides, measuring cytokine production (particularly IFN-γ), proliferative capacity, and cytotoxic activity.

• Phenotypic characterization: Analyze expression of memory markers (CD44, CD62L, CD127, KLRG1) to distinguish effector and central memory populations, which may be differentially affected by CD86 deficiency.

• Adoptive transfer experiments: Transfer CD8+ T cells from CD80/CD86−/− or wild-type mice into naive recipients, followed by viral challenge to assess autonomous memory defects versus environmental factors.

• Conditional knockout approaches: Utilize temporal or cell-specific deletion of CD86 to determine critical windows when CD86 costimulation impacts memory formation versus maintenance.

These approaches should be complemented by transcriptomic and epigenetic analyses to identify molecular pathways through which CD86 signaling influences memory CD8+ T-cell development and maintenance.

How can researchers reconcile divergent findings on CD86 function between different viral infection models?

Resolving seemingly contradictory findings on CD86 function across different viral infection models requires systematic comparative approaches. Studies with lymphocytic choriomeningitis virus (LCMV), influenza virus, vesicular stomatitis virus (VSV), and murine gammaherpesvirus 68 (MHV-68) all demonstrate importance of CD80/CD86-CD28 costimulation for antiviral CD8+ T-cell responses, but with varying magnitudes and kinetics .

To reconcile divergent findings, researchers should implement:

• Direct comparative studies using identical genetic backgrounds (CD80/CD86−/−, CD80−/−, CD86−/−, and CD28−/− mice) infected with different viruses under standardized conditions.

• Viral replication kinetics analysis to determine whether observed differences correlate with pathogen-specific replication rates and antigen persistence.

• Antigen load quantification to assess how differences in viral burden affect dependency on CD86 costimulation.

• APC-specific analyses to determine whether infection of different APC populations by various viruses alters CD86 expression patterns and subsequent T-cell activation.

• Tissue-specific investigation comparing CD86 requirements in different anatomical compartments (spleen, lymph nodes, lungs, liver) for various viral infections.

• Temporal blockade experiments using anti-CD86 antibodies at different infection phases to identify critical windows for CD86 requirements across infection models.

These methodological approaches can help identify virus-specific factors that influence dependency on CD86-mediated costimulation and resolve apparent contradictions in the literature.

What are the technical considerations when analyzing CD86 expression in relation to specialized T-cell subsets?

Analyzing CD86 expression and its impact on specialized T-cell subsets requires technical precision and awareness of several methodological pitfalls:

• Flow cytometry panel design: When analyzing CD86 expression alongside markers of specialized T-cell subsets (Tregs, Th1, Th2, Th17, T follicular helper cells), consider spectral overlap between fluorophores and include proper compensation controls. CD86 expression on APCs should be analyzed concurrently with markers defining APC subsets (dendritic cells, B cells, macrophages).

• Tissue preparation effects: Different tissue digestion protocols can affect CD86 epitope detection. Enzymatic digestion methods using collagenase should be carefully optimized to preserve CD86 epitopes while achieving sufficient tissue dissociation.

• Kinetic analyses: CD86 expression is dynamically regulated during immune responses, necessitating time-course experiments to capture transient interactions with various T-cell subsets.

• In situ visualization: Immunofluorescence or multiplex immunohistochemistry should be employed to analyze CD86-T cell interactions within tissue microenvironments, providing spatial context that flow cytometry cannot capture.

• Functional correlation: CD86 expression levels should be correlated with functional readouts (cytokine production, proliferation) of specific T-cell subsets through ex vivo stimulation assays or in vivo challenge models.

• Single-cell approaches: Consider using single-cell RNA sequencing to correlate CD86 expression with transcriptional profiles of interacting T cells, revealing subset-specific responses to CD86 costimulation.

These technical considerations ensure accurate interpretation of CD86's differential effects on specialized T-cell subpopulations.

How can researchers address variability in CD86 detection across different experimental platforms?

Variability in CD86 detection across different experimental platforms represents a significant challenge. Based on the performance data from ELISA-based detection systems, researchers should implement the following strategies:

• Standardization protocols: Establish reference standards for each experimental platform (flow cytometry, ELISA, immunohistochemistry). For ELISA, note that serum samples show a coefficient of variation of approximately 8.9%, while specific recovery rates range from 104-120% .

• Sample-specific optimization: Different sample types (serum, plasma with various anticoagulants) show varying recovery rates; EDTA plasma and citrate plasma samples typically show 96-112% recovery rates . Adjust protocols accordingly for each sample type.

• Antibody clone validation: When switching between detection platforms, validate that antibody clones used recognize the same epitopes on CD86. Some antibodies may preferentially detect specific conformational states of CD86.

• Inter-laboratory standardization: Establish common reference samples that can be analyzed across different laboratories to calibrate detection systems and enable meaningful cross-study comparisons.

• Pre-analytical variables control: Document and standardize sample collection, processing, and storage conditions, as these factors significantly impact CD86 stability and detectability.

These methodological considerations are essential for generating reproducible and comparable data on CD86 expression and function across different experimental systems.

What are the key considerations when interpreting CD8+ T-cell function in CD86-deficient experimental models?

Interpreting CD8+ T-cell functional data from CD86-deficient models requires careful consideration of several factors that might influence experimental outcomes:

• Developmental versus acute effects: CD86 deficiency can affect both T-cell development and acute activation. Researchers should distinguish between these by comparing constitutive knockouts with inducible or conditional knockout models or antibody blockade approaches.

• Compensatory mechanisms: CD80 may partially compensate for CD86 deficiency. Studies show that CD80/CD86−/− mice have more profound phenotypes than single knockouts, suggesting functional redundancy . Researchers should quantify potential upregulation of alternative costimulatory molecules in CD86-deficient settings.

• Context-dependent requirements: CD86's importance varies by infection phase. In MHV-68 infection, CD80/CD86−/− mice show severely impaired primary CD8+ T-cell expansion but normalized virus-specific CD8+ T-cell numbers by days 42 and 97 post-infection, despite functional deficiencies . Time-course analyses are essential.

• Environmental factors: Housing conditions and microbiome composition can influence baseline immune activation, potentially masking or exaggerating phenotypes in CD86-deficient mice. Standardized housing conditions and microbial profiling are recommended.

• Strain-specific effects: Genetic background influences dependency on costimulatory pathways. Researchers should maintain consistent genetic backgrounds and consider backcrossing knockout models to match experimental controls.

Understanding these variables is critical for accurate interpretation of experimental results involving CD86 deficiency and its impact on CD8+ T-cell function.

How should researchers control for off-target effects when using CD86 blocking antibodies in experimental systems?

When employing CD86 blocking antibodies, researchers must implement rigorous controls to distinguish specific from non-specific effects:

• Isotype controls: Always include matched isotype control antibodies at equivalent concentrations to control for Fc receptor-mediated effects. For example, when using anti-CTLA-4 monoclonal antibody (clone UC10-4F10-11) at 200 μg per intraperitoneal injection , an identical dosing schedule of isotype-matched control antibody should be administered to control groups.

• Genetic validation: Confirm antibody blocking effects by comparing with CD86−/− models. Absence of additional effects when administering CD86 blocking antibodies to CD86−/− mice would confirm specificity.

• Dose-response studies: Establish dose-response relationships to identify the minimal effective dose that achieves maximal CD86 blockade while minimizing off-target effects.

• Timing controls: CD86 blockade at different timepoints relative to immunological challenge may produce divergent outcomes. Include groups with varied administration schedules to identify critical windows for CD86 function.

• Cross-reactivity assessment: Test antibody specificity by confirming lack of binding to other B7 family members (particularly CD80) through competitive binding assays or by testing effects on CD80−/− cells.

• Epitope targeting: Consider that different antibody clones may recognize distinct CD86 epitopes, potentially differentially blocking interactions with CD28 versus CTLA-4. Characterize binding properties of blocking antibodies before experimental use.

These methodological controls ensure that observed phenotypes specifically reflect CD86 blockade rather than experimental artifacts.

What statistical approaches are most appropriate for analyzing CD86 expression data across different experimental conditions?

Selecting appropriate statistical methods for CD86 expression analysis requires consideration of data distribution, experimental design, and biological variability:

• Normality testing: Before applying parametric tests, verify data normality using Shapiro-Wilk or Kolmogorov-Smirnov tests. CD86 expression data, particularly from flow cytometry, often follows non-normal distributions requiring non-parametric analyses.

• Paired analyses for longitudinal studies: For studies measuring CD86 expression over time, paired statistical tests (paired t-test or Wilcoxon signed-rank test) provide greater statistical power by controlling for subject-specific variability.

• Multiple group comparisons: When comparing CD86 expression across multiple experimental conditions, use ANOVA (parametric) or Kruskal-Wallis (non-parametric) with appropriate post-hoc tests (Tukey's or Dunn's) with correction for multiple comparisons.

• Correlation analyses: When correlating CD86 expression with functional outcomes (e.g., T-cell proliferation, cytokine production), select Pearson (parametric) or Spearman (non-parametric) correlation coefficients based on data distribution.

• Sample size considerations: Based on observed coefficients of variation in CD86 ELISA measurements (4.74-8.9%) , power calculations should account for this inherent variability when determining appropriate sample sizes.

• Multi-parameter analysis: For complex datasets correlating CD86 with multiple immune parameters, consider multivariate approaches such as principal component analysis or partial least squares discriminant analysis to identify patterns not evident in univariate analyses.

These statistical approaches ensure robust interpretation of CD86 expression data while accounting for biological and technical variability inherent in immunological experiments.

How can researchers accurately interpret the significance of CD86 expression changes in disease models?

Interpreting CD86 expression changes in disease models requires contextualizing data within broader immunological parameters:

• Baseline calibration: Establish normal variation in CD86 expression across relevant tissues and cell types in healthy controls. Expression changes should be interpreted relative to this range rather than absolute values.

• Cell-specific analysis: Changes in bulk CD86 levels may reflect altered cellular composition rather than per-cell expression changes. Flow cytometric analysis providing cell-specific CD86 quantification is preferable to whole-tissue measurements.

• Functional correlation: Correlate CD86 expression changes with functional readouts, including T-cell activation markers, cytokine production, and disease-specific parameters to establish biological significance beyond statistical differences.

• Temporal dynamics: Single-timepoint measurements may miss critical expression dynamics. Longitudinal sampling throughout disease progression provides more meaningful interpretation of CD86's role in pathogenesis.

• Intervention studies: Determine causality through interventional approaches, including CD86 blockade or overexpression at different disease stages. This distinguishes disease-driving versus compensatory expression changes.

• Cross-species validation: Validate findings across multiple model systems when possible. CD86 function may vary between mouse strains or between murine models and human disease, requiring cautious extrapolation.

These interpretative frameworks help distinguish biologically significant CD86 expression changes from statistical fluctuations or epiphenomena in disease models.

What emerging technologies show promise for studying CD86-dependent costimulatory mechanisms at the single-cell level?

Several cutting-edge technologies are revolutionizing our ability to study CD86-mediated costimulation with unprecedented resolution:

• Single-cell transcriptomics with spatial resolution: Spatial transcriptomics techniques allow researchers to map CD86 expression patterns within tissue microenvironments while simultaneously assessing transcriptional responses in interacting T cells, providing insights into localized costimulatory effects.

• Live cell imaging with optogenetics: Combining fluorescent reporter systems with optogenetic control of CD86 signaling enables real-time visualization and manipulation of costimulatory interactions at the immunological synapse, revealing the temporal dynamics of CD86-mediated signaling.

• CRISPR-based screening approaches: Pooled CRISPR screens targeting CD86 regulatory elements or downstream signaling components can identify novel molecular players in CD86-dependent costimulation pathways, potentially revealing therapeutic targets.

• Mass cytometry (CyTOF): This technique allows simultaneous measurement of CD86 expression alongside dozens of other cellular markers, enabling comprehensive phenotyping of CD86-expressing cells and responding T cells across different disease states and experimental conditions.

• Proximity labeling proteomics: Techniques like TurboID or APEX2 fused to CD86 can identify proximal protein interactions occurring during costimulation, mapping the dynamic protein interactome at the CD86-CD28/CTLA-4 interface.

• Single-molecule tracking: Super-resolution microscopy combined with single-molecule tracking can reveal the nanoscale organization and dynamics of CD86 molecules during formation of the immunological synapse, providing insights into the biophysical aspects of costimulation.

These emerging technologies promise to transform our understanding of CD86-mediated costimulation from population-level observations to molecular events at single-cell resolution.

How might targeting CD86-dependent pathways contribute to next-generation immunotherapeutic approaches?

Targeting CD86-dependent pathways holds significant potential for novel immunotherapeutic strategies: